OrbiMed

Garuda Therapeutics is a biotechnology company focused on creating off-the-shelf hematopoietic stem cell therapies aimed at treating various severe and life-threatening conditions. The company specializes in addressing blood, bone marrow, immune, and metabolic diseases. By leveraging expertise in innovative research methods, including the use of zebrafish, mice, and human-induced pluripotent stem cells, Garuda analyzes novel genes and mechanisms vital for blood formation. This approach enables the development of mechanism-based therapies designed to improve patient outcomes.

Caris Life Sciences is a biotechnology company based in Irving, Texas, specializing in precision medicine and cancer treatment. Founded in 1996, the company develops and commercializes advanced diagnostic technologies, including anatomic pathology and molecular profiling, to enhance the understanding of cancer biology. Its services encompass comprehensive molecular analyses of patient samples, integrating genomic, transcriptomic, and proteomic profiling through the Caris Molecular Intelligence platform. This platform aids physicians and cancer patients in making informed and personalized treatment decisions by revealing the molecular blueprint of complex diseases. Caris Life Sciences serves a global customer base through distributors in regions including the United States, Europe, and Australia, and maintains a strategic collaboration with Debiopharm International SA. The company is committed to improving patient outcomes through innovative scientific advancements and a focus on quality care.

Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.

Acelyrin is a late-stage clinical biopharmaceutical company dedicated to delivering innovative treatment options to patients. The company specializes in identifying, acquiring, and accelerating the development and commercialization of promising drug candidates. By leveraging its expertise, Acelyrin aims to advance transformative medicines that can significantly improve patient outcomes.

Adaptive Biotechnologies is a commercial-stage company focused on advancing immune-driven medicine by leveraging the biology of the adaptive immune system for disease diagnosis and treatment. Founded in 2009 and headquartered in Seattle, Washington, the company offers a range of products and services, including the immunoSEQ research service and kit, which aids in research and the discovery of diagnostic signals. Its FDA-authorized clonoSEQ diagnostic test is designed for the detection and monitoring of minimal residual disease in patients with specific blood cancers. Additionally, Adaptive Biotechnologies is developing a pipeline of clinical products aimed at diagnosing and treating cancer, autoimmune conditions, and infectious diseases. The company has formed strategic collaborations with notable partners, including Genentech for neoantigen-directed T cell therapies, Microsoft for early disease detection tests from blood samples, and Amgen for therapeutic development related to COVID-19.

Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, that focuses on the early detection of cancer through non-invasive blood tests. Founded in 2018, the company utilizes advanced technologies such as artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in patients' blood. By leveraging machine learning, Delfi develops innovative testing systems aimed at recognizing cancer-associated cell-free DNA fragments, thereby enabling healthcare professionals to detect cancer at its most treatable stage. This approach facilitates timely and effective treatment options, ultimately aiming to improve patient outcomes and recovery speed.

X4 Pharmaceuticals is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing novel therapeutics for primary immune deficiencies and cancer. Its lead drug candidate, mavorixafor, is an oral small molecule antagonist of the chemokine receptor CXCR4 and is currently undergoing various clinical trials, including a Phase III trial for patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, as well as trials for severe congenital neutropenia and clear cell renal cell carcinoma. The company is also advancing X4P-002, which targets glioblastoma multiforme, and X4P-003, aimed at treating primary immune deficiencies. Additionally, X4 Pharmaceuticals has a collaboration with Abbisko Therapeutics to explore mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. before rebranding in 2019.

Frontera Therapeutics is an AAV gene therapy company with the mission to establish a low-cost and scalable platform, to develop and produce high-quality and affordably priced rAAV therapies for the global market.

Aerin Medical Inc. is a health technology company based in Sunnyvale, California, focused on developing non-invasive treatment solutions for nasal breathing disorders. Founded in 2011, the company specializes in therapeutic devices that utilize low-power radiofrequency energy to remodel nasal soft tissues, effectively addressing the underlying causes of conditions such as nasal obstruction and chronic rhinitis. Aerin Medical offers procedures and devices, including the VivAer procedure and the RhinAer procedure, along with their corresponding styluses, which allow ENT physicians to treat nasal airway conditions in an office setting under local anesthesia. These innovative solutions aim to improve patient outcomes by providing safe, quick, and effective relief from chronic nasal symptoms while minimizing downtime.

DarioHealth Corp. is a digital health company that specializes in developing and commercializing proprietary technology for laboratory testing via smartphones and mobile devices. Its flagship product, the Dario Smart Diabetes Management Solution, integrates a cloud-based software application with a compact blood glucose monitoring device. This solution enables users to manage their diabetes through real-time data tracking, coaching, and support, while also providing alerts and analysis of health trends. DarioHealth markets its products directly to consumers and through retail pharmacies, hospitals, and online channels. The company also offers a digital platform, DarioEngage, to enhance user engagement and support in managing chronic illnesses. Founded in 2011 and headquartered in Caesarea, Israel, DarioHealth emphasizes personalized, evidence-based interventions driven by data analytics and individual coaching, addressing various health concerns such as diabetes, hypertension, and weight management.

Upstream Bio is a clinical-stage biotechnology company established in 2004 and headquartered in the United States. The company specializes in developing antibody therapies aimed at treating inflammatory diseases, with a primary focus on severe respiratory disorders, particularly severe asthma. Upstream Bio is advancing its lead candidate, verekitug, an antagonist that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine known to play a significant role in driving inflammatory responses. The approach of targeting TSLP positions Upstream Bio to address various immune-mediated conditions by intervening at a crucial point in the signaling pathways involved in inflammation.

Terremoto Biosciences is a biotechnology company focused on drug delivery and discovery, specializing in small-molecule medicines. The company utilizes lysine-based covalency to develop optimized therapies with enhanced clinical profiles and superior therapeutic benefits. Terremoto's innovative platform aims to improve existing medicines and create new treatments for serious diseases, contributing to advancements in the healthcare sector.

Aspen Neuroscience, Inc. is a biotechnology company based in San Diego, California, focused on developing induced pluripotent stem cell therapies for neurological conditions, particularly Parkinson's disease. Founded in 2018, the company aims to create patient-specific restorative cell therapies that can alter the progression of the disease. Its product pipeline includes ANPD001, an autologous neuron replacement therapy designed for sporadic Parkinson's disease, and ANPD002, a gene-edited version targeting familial forms of the disease. By integrating innovative genomic approaches with stem cell biology, Aspen Neuroscience seeks to advance the field of personalized medicine and improve treatment outcomes for patients suffering from Parkinson's disease.

Valneva SE is a specialty vaccine company dedicated to the development and commercialization of vaccines for infectious diseases that lack adequate solutions. The company offers two commercial vaccines for travelers: IXIARO/JESPECT, which protects against Japanese encephalitis, and DUKORAL, aimed at preventing cholera and certain types of diarrhea. Valneva is also advancing several vaccine candidates, including the only developmental vaccine for Lyme disease and a single-shot vaccine for chikungunya. Founded in 1999, Valneva operates in multiple countries, including Austria, Canada, France, Sweden, the United Kingdom, and the United States. The company is involved in a collaboration with Dynavax Technologies Corporation to further vaccine development for COVID-19. Valneva's focus is on addressing urgent public health needs through innovative vaccine solutions.

Developer of life sciences technology intended to develop highly effective and differentiated treatments for cystic fibrosis. The company is developing first-in-class small molecules that are focused on a unique target with the potential to fully normalize CFTR function for the first time for the vast majority of people living with cystic fibrosis, enabling patients with best-in-class efficacy and reach and long-term benefit for people with cystic fibrosis.

Electra Therapeutics is a clinical-stage biotechnology company focused on developing therapies that target signal regulatory proteins (SIRP) for treating immunological diseases and cancer. The company has one program in clinical development and two additional preclinical programs. Its lead product candidate, ELA026, is a monoclonal antibody designed to target SIRP on the surface of myeloid and T cells, effectively depleting pathological immune cells. ELA026 is currently being investigated for secondary hemophagocytic lymphohistiocytosis (sHLH), a severe hyperinflammatory condition for which no approved treatment exists.

ArriVent Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative treatments for cancer. The company aims to address unmet medical needs by leveraging its team's extensive experience in drug development. ArriVent is advancing its lead candidate, furmonertinib, along with a pipeline of novel therapeutics, including next-generation antibody-drug conjugates. The company's initial emphasis is on solid tumors, reflecting its commitment to improving outcomes for cancer patients through differentiated medicines.

ImmPACT Bio USA Inc. is a cell therapy company aiming to develop potent and selective engineered T-cells for the treatment of solid tumors. The Company's technology enables targeting loss-of-gene features of solid tumor cells, sparing normal, healthy tissues.

Alterome Therapeutics is a precision oncology biotech developing alteration-specific therapeutics to address high value and validated oncogenic drivers.

Odyssey Therapeutics is a biotechnology company pioneering the efficient development of next-generation immunomodulators and oncology medicines. Odyssey is making a transformational impact on the field of drug discovery and is accelerating the path to clinical development to drive the creation of more effective precision medicines.

Cyrus Biotechnology builds software tools to accelerate basic research in biotech, pharma, and industrial biotechnology. Cyrus Bench delivers an enterprise version of the Rosetta molecular modeling and design toolkit, with the associated array of bio-molecular computation tools. It was founded in 2014 and headquartered in Seattle, Washington.

Alpheus Medical provides a novel sonodynamic therapy platform targeting solid body cancers. Alpheus Medical also provides a non-invasive drug-device combination for outpatient treatment of recurrent glioblastoma multiforme (rGBM).

Acelyrin is a late-stage clinical biopharmaceutical company dedicated to delivering innovative treatment options to patients. The company specializes in identifying, acquiring, and accelerating the development and commercialization of promising drug candidates. By leveraging its expertise, Acelyrin aims to advance transformative medicines that can significantly improve patient outcomes.

Tricida, Inc. is a pharmaceutical company based in South San Francisco, California, established in 2013. The company is dedicated to the development and commercialization of its lead product candidate, TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis, a condition often associated with CKD, can hasten kidney deterioration and lead to serious complications such as muscle wasting and loss of bone density. Tricida has successfully completed a Phase 3, double-blind, placebo-controlled trial of TRC101, which aims to bind and remove acid from the gastrointestinal tract, thereby addressing the underlying metabolic issues and potentially slowing the progression of CKD.

PierianDx, Inc. is a technology company that develops a genomic software-as-a-service (SaaS) solution designed to manage, analyze, and interpret complex genomic tests for clinical laboratories in the United States. The company offers the Clinical Genomicist Workstation, a platform that streamlines the workflow for patient cases, handling everything from sequencing and analysis to report generation and integration with electronic health records. PierianDx aims to enhance the adoption of genomic sequencing in healthcare, enabling physicians to diagnose and treat patients with cancer and other complex diseases more effectively. The company also provides consulting and technical services to support its clients, which include health systems, children's hospitals, comprehensive cancer centers, and reference laboratories. Founded in 2014 and headquartered in Saint Louis, Missouri, PierianDx has established itself as a trusted source for advanced genomic reporting and decision support in clinical care.

ReCode Therapeutics is a development-stage biopharmaceutical company focused on the correction of the nonsense mutations that account for 1/3 of all inherited diseases, including approximately 10% of cystic fibrosis. They have combined selected tRNAs with their unique and diverse proprietary delivery platforms to create and develop first-in-class suppressor tRNA-nanoparticle therapeutics for correcting nonsense mutations. ReCode’s diverse pipeline includes lead programs for primary ciliary dyskinesia (PCD) and nonsense mutations in cystic fibrosis (CF). The company’s proprietary non-viral lipid nanoparticle platform enables the delivery of a variety of payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. ReCode is leveraging its nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated protein replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing. The company was founded in 2015 and is based in Dallas, Texas.

Scout Bio, Inc. researches and develops one-time therapies for major chronic pet health conditions using veterinary biotechnology and gene therapy. It offers therapies for anemia associated with chronic kidney disease (CKD) in cats. The company offers pet therapeutics, including small molecular drugs, protein therapies, and gene therapies. Scout Bio, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Garuda Therapeutics is a biotechnology company focused on creating off-the-shelf hematopoietic stem cell therapies aimed at treating various severe and life-threatening conditions. The company specializes in addressing blood, bone marrow, immune, and metabolic diseases. By leveraging expertise in innovative research methods, including the use of zebrafish, mice, and human-induced pluripotent stem cells, Garuda analyzes novel genes and mechanisms vital for blood formation. This approach enables the development of mechanism-based therapies designed to improve patient outcomes.

Ventyx Biosciences, Inc. is a biotechnology company based in Encinitas, California, focused on developing selective inhibitors of TYK2 for the treatment of autoimmune diseases. Incorporated in 2018, the company boasts a diverse portfolio of innovative clinical and pre-clinical programs aimed at high-value therapeutic targets. Through its research and development efforts, Ventyx is committed to advancing treatments that address unmet medical needs in the autoimmune disease space.

Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, specializing in the discovery and development of protein-based immunotherapies aimed at treating cancer, autoimmune, and inflammatory disorders. The company's lead programs include ALPN-101, an antagonist targeting the inducible T cell costimulator and CD28 pathways for autoimmune and inflammatory diseases, and ALPN-202, which combines programmed cell death protein ligand 1 and cytotoxic T-lymphocyte associated protein 4 antagonism with PD-L1 dependent CD28 costimulation for cancer treatment. Additionally, Alpine has a collaboration with Kite Pharma, Inc. to develop immunotherapies that target the immune synapse for cancer therapy. The company utilizes a proprietary platform to transform native immune system proteins into innovative, multi-targeted therapeutics.

iECURE is a biotechnology company focused on developing gene editing therapies aimed at treating rare and life-threatening liver disorders, particularly in children. The company employs mutation-agnostic in vivo gene insertion techniques, which allow for targeted therapeutic interventions without being limited by specific genetic mutations. Its initial programs concentrate on addressing metabolic "loss of function" disorders, which often have significant unmet medical needs. Through its innovative approach, iECURE aims to provide effective treatments for devastating diseases that currently lack viable options.

ADARx Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on the research and development of RNA editing therapeutics. Founded in 2019, the company specializes in utilizing a proprietary platform that leverages endogenous enzymes, specifically adenosine deaminase acting on RNA (ADAR), to precisely target and correct single point mutations in mRNA transcripts. This innovative approach aims to restore the production of functional proteins, addressing various genetic mutations that contribute to diseases. ADARx is developing a pipeline of therapeutics designed to treat a range of conditions, including genetic, cardiometabolic, complement-mediated, and central nervous system diseases, offering potential solutions for previously incurable ailments.

Disc Medicine, Inc. is a biotechnology company focused on developing therapeutics based on human genetics to address ineffective red blood cell production in hematologic diseases. The company specializes in programs targeting the hepcidin metabolism axis for the treatment of disorders related to hepcidin. Founded in 2017 and headquartered in Cambridge, Massachusetts, Disc Medicine is led by a team of experienced scientists and industry experts, supported by a panel of advisors with a proven history in discovering and developing innovative therapies. The company was established with backing from Atlas Venture, along with contributions from Novo Ventures and Access Biotechnology.

Humacyte, Inc. is a medical research and development company based in Morrisville, North Carolina, focused on creating and commercializing human tissue-based products for regenerative medicine and vascular surgery. Founded in 2004, the company specializes in developing acellular extracellular matrices derived from banked vascular smooth muscle cells, which are decellularized to prevent rejection. These matrices serve as tissue-engineered grafts, providing solutions for patients requiring vascular repair or replacement. Humacyte's innovative biotechnology platform aims to deliver universally implantable bioengineered human tissues and organs, addressing a variety of diseases, injuries, and chronic conditions, ultimately seeking to enhance patient outcomes and transform medical practices.

Neurogastrx, Inc. is a venture-stage biopharmaceutical company focused on developing innovative therapies for gastrointestinal disorders. Established in 2017 and located in Campbell, California, the company aims to address the unmet medical needs associated with functional and motility disorders of the gastrointestinal tract. One of its key products, NG101, is designed to enhance gastric motility while also possessing antiemetic properties. Neurogastrx's specialty therapies target the enteric nervous system, addressing issues related to gut contractions, sensation, and the brain-gut axis, ultimately striving to alleviate the burden of these disorders on patients and the healthcare system.

Vigil will use the Series A funds to progress its lead pipeline candidate, a monoclonal antibody TREM2 agonist, through Phase 1 studies, advance their small molecule TREM2 agonist to IND, as well as pursue additional assets to grow the pipeline and increase the body of data supporting microglia biology as an important therapeutic pathway.

Carrot Fertility, Inc. provides comprehensive fertility benefits services to employers, supporting employees throughout their fertility healthcare journey globally. Founded in 2015 and headquartered in San Francisco, the company offers a range of services, including egg freezing, in vitro fertilization, adoption, donor, and gestational carrier services. Additionally, it features Carrot Rx, which facilitates a premium pharmacy experience for fertility medications, and Carrot Pregnancy, providing virtual access to experts and on-demand content. Carrot Card is a flexible benefits debit card that allows employees to pay for their care. By partnering with modern companies, Carrot Fertility enables organizations to customize fertility benefits that deliver financial, medical, and emotional support to employees seeking to become parents. The company also has offices in major cities around the world, including Chicago, New York, Dublin, Geneva, Tokyo, and Seoul.

GentiBio, Inc. is a biotherapeutics company focused on developing engineered regulatory T cells (EngTregs) to treat a range of conditions, including autoimmune, alloimmune, autoinflammatory, and allergic diseases. Founded in 2020 and based in Boston, Massachusetts, with additional locations in Seattle and Israel, GentiBio utilizes a proprietary platform that combines autologous and allogeneic EngTregs. This innovative approach aims to restore immune tolerance and address the limitations found in current regulatory T-cell therapies. The company was co-founded by experts in Treg biology and synthetic immunology, emphasizing its commitment to addressing the underlying causes of diseases linked to immune system dysfunction.

XtalPi Inc. is a pharmaceutical technology company founded in 2014 and headquartered in Cambridge, Massachusetts, with additional offices in China. The company specializes in leveraging artificial intelligence and advanced computing to accelerate drug development. Its offerings include XtalForc, a visual force field calculation software; XtalVision, a tool for crystal structure prediction; and Renova, which supports AI-driven research and development. XtalPi provides a range of services such as crystal structure prediction and determination, solid state testing and analysis, crystallization process development, and small molecule drug design. By collaborating with pharmaceutical companies, XtalPi uses its predictive algorithms to facilitate the development of new drugs and the creation of patents, enhancing the efficiency of the drug discovery process.

XinThera is a drug discovery company dedicated to developing precision medicines aimed at treating cancer and immunologic diseases. By utilizing advanced computational chemistry technologies, XinThera designs small molecule therapies that target well-validated and previously challenging targets in oncology and immunology. The company's focus on these promising targets enhances the potential for effective drug therapies, ultimately benefiting patients who face difficult-to-treat conditions.

Owlet Baby Care Inc. is a company that develops and manufactures innovative monitoring products designed to track the vital signs of sleeping infants. Founded in 2012 and based in Lehi, Utah, Owlet offers the Owlet Smart Sock, a device that monitors an infant's heart rate and oxygen levels, alerting parents if there are any concerns. The Owlet Baby Monitor provides real-time data on a child's vital signs through a compatible app for iOS and Android devices, giving parents peace of mind. The company's product range also includes the Owlet Cam, which transforms smartphones into high-definition baby monitors, and the Owlet Monitor Duo, which combines the features of the Smart Sock with the Cam. Additionally, the Owlet Dream Lab offers resources to help parents establish healthy sleep habits for their children. Owlet's commitment to enhancing parental confidence through technology is reflected in its diversified product portfolio.

Turnstone Biologics Inc. is a biotechnology company dedicated to developing viral immunotherapies aimed at enhancing cancer survival rates. Founded in 2015 and headquartered in Ottawa, Canada, with an additional office in New York, the company’s lead candidate, RIVAL-01, is based on a vaccinia virus backbone that incorporates three effective immunomodulators: Flt3 ligand, anti-CTLA-4 antibody, and IL-12 cytokine. These components are designed to synergistically stimulate immune responses and modify the tumor microenvironment to facilitate tumor eradication. Turnstone's platform leverages discoveries from prominent researchers in the field of oncolytic viral immunotherapy and has progressed RIVAL-01 into a Phase I/II clinical development study in collaboration with four Canadian academic institutions and the Fight Against Cancer Innovation Trust (FACIT).

Iambic Therapeutics focuses on accelerating molecular discovery through its innovative quantum molecular simulation engine. By integrating artificial intelligence and automated synthetic development, the company aims to enhance the design of small-molecule therapeutics. This technology significantly improves the accuracy of molecular predictions, providing valuable insights for therapeutic discovery. Iambic Therapeutics is committed to transforming the drug development process, enabling physicians to access more precise molecular data and ultimately improving treatment outcomes.

ArriVent Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative treatments for cancer. The company aims to address unmet medical needs by leveraging its team's extensive experience in drug development. ArriVent is advancing its lead candidate, furmonertinib, along with a pipeline of novel therapeutics, including next-generation antibody-drug conjugates. The company's initial emphasis is on solid tumors, reflecting its commitment to improving outcomes for cancer patients through differentiated medicines.

Biocytogen is a biotechnology company that specializes in developing gene-targeted animal models for life science research. Founded in 2008, with headquarters in Beijing, China, and additional facilities in the United States, Biocytogen offers a range of services including customized and off-the-shelf mouse models, as well as phenotype analysis across various biological areas such as immunology, neurology, and cancer. The company utilizes advanced gene-targeting platforms to create a variety of genetically modified animals, including humanized models and knockouts, to support preclinical studies. Biocytogen also provides pharmacology services related to tumor immunity and autoimmunity, and it markets its products online. With a commitment to integrating resources from both China and the United States, Biocytogen aims to be a leading global supplier of gene-targeted animal models.

InSilico Medicine, Inc. is an artificial intelligence company focused on drug discovery, biomarker development, and aging research. Founded in 2014 and headquartered in Baltimore, Maryland, the company employs advanced AI technologies, including deep learning and generative adversarial networks, to create novel molecular structures for diseases with known and unknown targets. Its comprehensive platform covers all stages of drug development, from discovery to clinical trials. Key initiatives include Pharma.AI, which offers machine learning services to various industries, and Young.AI, which predicts biological age. InSilico Medicine also engages in internal drug discovery programs targeting conditions such as cancer, Parkinson's Disease, and age-related disorders. Additionally, the company has partnered with Life Extension to develop nutraceutical products using its bioinformatics and deep learning techniques. Through its innovative solutions, InSilico Medicine aims to enhance personalized healthcare and mitigate the effects of aging.

RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. The company specializes in developing tumor-targeted small molecule medicines that utilize radioisotopes, particularly focusing on alpha-emitting isotopes like Actinium-225 for the treatment of solid tumors. RayzeBio aims to improve cancer treatment outcomes by creating a robust pipeline of radiopharmaceuticals targeting validated oncology drug targets. Its portfolio includes multiple drug candidates at various stages of development, ranging from discovery to late-stage clinical programs, addressing significant market opportunities in the field of cancer therapeutics.

Nautilus Biotechnology is a development-stage life sciences company focused on advancing proteomics, the study of proteins and their functions, to enhance therapeutic development and medical diagnostics. The company has created a platform technology that aims to quantify and unravel the complexities of the human proteome. Its flagship product, the Proteomic Analysis System, is a prototype single-molecule instrument designed to facilitate these efforts. The team at Nautilus comprises experts from various disciplines, including protein chemistry, molecular biology, and data science, enabling a multifaceted approach to overcoming challenges in the field. By harnessing this diverse expertise, Nautilus aims to revolutionize drug development and improve healthcare management through personalized and predictive medicine.

Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, specializing in the development of diagnostic instruments and disposable cartridge systems for decentralized laboratory and point-of-care environments. The company's flagship products include the io System, which detects infectious diseases such as chlamydia and MRSA, and Callisto, designed to accommodate various testing throughput requirements. Binx Health focuses on providing solutions for sexually transmitted infections and hospital-acquired infections. The company aims to enhance healthcare accessibility by delivering on-demand testing directly to consumers, utilizing its proprietary, desktop, PCR-based platforms and mobile offerings. Established in 2005, Binx Health has formed a strategic partnership with Sherlock Biosciences to further advance its innovative healthcare solutions.

Sparrow Pharmaceuticals, founded in 2013 and based in Portland, Oregon, focuses on developing targeted therapies for conditions related to corticosteroid excess. The company aims to provide innovative treatment options for disorders linked to elevated levels of cortisol, which can arise from tumors or prolonged use of corticosteroid medications like prednisone. By addressing serious issues associated with hypercortisolism, Sparrow Pharmaceuticals seeks to enhance the management of autoimmune and inflammatory conditions, ultimately improving patient care and outcomes in this challenging medical area.

Magenta is focused on improving the patient experience in transplant medicine, with the goal of bringing this lifesaving procedure to more patients. Over the past 50 years, stem cell transplantation has been used in more than 1M patients worldwide. It is currently the only treatment with the potential to cure some of the most devastating hematologic cancers and autoimmune diseases. Despite the increased use and clinical advancements over the past several decades, stem cell transplant remains a high-risk last-resort therapeutic option due to the toxicity and potential long-term side effects.

Caris Life Sciences is a biotechnology company based in Irving, Texas, specializing in precision medicine and cancer treatment. Founded in 1996, the company develops and commercializes advanced diagnostic technologies, including anatomic pathology and molecular profiling, to enhance the understanding of cancer biology. Its services encompass comprehensive molecular analyses of patient samples, integrating genomic, transcriptomic, and proteomic profiling through the Caris Molecular Intelligence platform. This platform aids physicians and cancer patients in making informed and personalized treatment decisions by revealing the molecular blueprint of complex diseases. Caris Life Sciences serves a global customer base through distributors in regions including the United States, Europe, and Australia, and maintains a strategic collaboration with Debiopharm International SA. The company is committed to improving patient outcomes through innovative scientific advancements and a focus on quality care.

Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology. GMAB is an adaptive technology that uses a novel, cell-penetrating antibody to non-covalently bind to and deliver therapeutic levels of a wide variety of nucleic acid payloads to select cells. This non-viral delivery platform is differentiated from traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and employs well-established manufacturing processes. Gennao Bio is developing this delivery system with an initial focus on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases.

Treeline Biosciences is a biotech company building transformative precision medicines for patients with cancer and other serious conditions. The company was founded in 2021 and is headquartered in Stamford, CT.

Janux Therapeutics develops immunotherapies that generate immune responses to prevent tumors and not affecting a patient’s healthy tissue. Janux technology targets all three stages of the anti-tumor immune response. Janux Therapeutics, Inc. was founded in 2017 by David Campbell and is based in La Jolla, California.

Invivyd is a biotechnology company focused on developing advanced antibodies to neutralize SARS-CoV-2, SARS-CoV-1, and other potentially emerging coronaviruses. Founded in 2020 and headquartered in Waltham, Massachusetts, the company aims to create best-in-class therapeutic and prophylactic treatments that surpass the efficacy of existing antibody programs. Its innovative portfolio features multiple non-competing antibodies, each targeting distinct viral epitopes, which is designed to minimize the risk of viral escape. By leveraging cutting-edge antibody discovery technologies, Invivyd seeks to enhance the potency and durability of its antibody candidates, addressing a critical need in the ongoing fight against coronaviruses.

Theseus Pharmaceuticals is a Technology based company.

Developer of a computer-assisted radiology technology designed to enhance efficiency and effectiveness in imaging-guided cancer treatment. The company's technology offers a platform that supports a patient-specific, disease-targeted and multi-disciplinary approach to cancer treatment, enabling physicians to use advanced clinical applications, including automated volumetric organ segmentation and virtual planning and treatment simulation.

Scribe Therapeutics Inc. is a biotechnology company focused on developing innovative therapeutics using CRISPR technology to address genetic disorders. Founded in 2017 and based in Berkeley, California, Scribe specializes in engineering CRISPR enzymes known as X-Editing (XE) molecules, which enhance the efficacy, specificity, and deliverability of genome editing compared to existing methods. The company's proprietary platform enables the creation of custom-engineered enzymes and delivery systems, facilitating precision targeting within the genome. Scribe Therapeutics aims to establish CRISPR-based therapies as a standard in clinical care, expanding access to transformative treatments for a wide range of conditions, including immuno-oncology and degenerative disorders. Through its commitment to overcoming the limitations of current genome editing technologies, Scribe Therapeutics is poised to make substantial contributions to human therapeutics.

Crossover Health, Inc. is a healthcare provider focused on delivering comprehensive workplace healthcare services tailored for employers and their employees. Founded in 2010 and headquartered in Aliso Viejo, California, the company operates health centers in various locations, including Silicon Valley. Crossover Health offers a wide range of services, such as primary care, urgent care, preventive care, chronic disease management, health education, physical therapy, and remote care, among others. By integrating various health and wellness benefits with technology-enabled services, Crossover Health aims to enhance access to care and reduce healthcare costs for companies. The firm collaborates closely with client partners to customize health services based on health analytics, fostering a culture of health ownership among employees while improving both the quality of care and the overall employee experience.

X4 Pharmaceuticals is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing novel therapeutics for primary immune deficiencies and cancer. Its lead drug candidate, mavorixafor, is an oral small molecule antagonist of the chemokine receptor CXCR4 and is currently undergoing various clinical trials, including a Phase III trial for patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, as well as trials for severe congenital neutropenia and clear cell renal cell carcinoma. The company is also advancing X4P-002, which targets glioblastoma multiforme, and X4P-003, aimed at treating primary immune deficiencies. Additionally, X4 Pharmaceuticals has a collaboration with Abbisko Therapeutics to explore mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. before rebranding in 2019.

Graphite Bio is a gene editing company focused on targeted DNA integration to address severe diseases. The company employs technology that enables the insertion of new genetic sequences to replace defective genes, repair damaged portions of genes, and insert therapeutic genetic material at specific locations within the genome. This precise approach leverages natural cellular DNA repair mechanisms to enhance the efficiency of gene integration, aiming to correct the underlying causes of various diseases. Founded in 2019 and based in South San Francisco, California, Graphite Bio was previously known as Integral Medicines, Inc. and rebranded in August 2020. The company is committed to advancing gene replacement therapies and potential cures for individuals affected by serious health conditions.

Ventyx Biosciences, Inc. is a biotechnology company based in Encinitas, California, focused on developing selective inhibitors of TYK2 for the treatment of autoimmune diseases. Incorporated in 2018, the company boasts a diverse portfolio of innovative clinical and pre-clinical programs aimed at high-value therapeutic targets. Through its research and development efforts, Ventyx is committed to advancing treatments that address unmet medical needs in the autoimmune disease space.

Century Therapeutics, Inc. is a biotechnology company focused on developing induced pluripotent stem cell (iPSC)-based therapies for cancer treatment. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, the company aims to create allogeneic living drugs that specifically target both hematologic and solid tumors. By utilizing iPSCs, Century Therapeutics can engineer immune effector cells through multiple rounds of cellular modification, producing master cell banks that can be expanded and differentiated for therapeutic use. Their innovative approach incorporates advanced technologies such as CRISPR-mediated gene editing and proprietary chimeric antigen receptors, along with Allo-Evasion technology, which helps prevent rejection by the host immune system. These advancements position Century Therapeutics to enhance the effectiveness and accessibility of cancer treatments.

Janux Therapeutics develops immunotherapies that generate immune responses to prevent tumors and not affecting a patient’s healthy tissue. Janux technology targets all three stages of the anti-tumor immune response. Janux Therapeutics, Inc. was founded in 2017 by David Campbell and is based in La Jolla, California.

BlossomHill Therapeutics, Inc. is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders.

Yisheng Biopharma Co., Ltd. is a biopharmaceutical company focused on the research, development, manufacturing, and marketing of immuno-oncology products and vaccines. Founded in 2002 and headquartered in Beijing, the company operates in China, the United States, Cambodia, and Singapore. Yisheng Biopharma utilizes its novel PIKA immunomodulating technology to enhance immune responses against cancers and infectious diseases. Key products under development include YS-ON-001, an investigational therapy aimed at treating advanced solid tumors, as well as YS-HBV-001, a vaccine for hepatitis B, and a PIKA-based rabies vaccine designed for rapid protection against rabies infection. The company's innovative approach targets multiple immune pathways to improve treatment outcomes.

Gemini Therapeutics, Inc. is a precision medicine company established in 2015 and based in Cambridge, Massachusetts. The company specializes in developing therapies for patients with dry age-related macular degeneration (AMD) and related rare genetic diseases. Gemini's approach focuses on addressing genetically-defined conditions by creating therapeutic candidates that target specific molecular abnormalities prevalent in patients with significant clinical needs. Their diverse pipeline features a range of innovative treatment modalities, including monoclonal antibodies, recombinant proteins, and gene therapies. The company has secured funding from prominent life science investors and collaborates with academic institutions globally to advance its mission of delivering potentially first-in-class therapeutics.

Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, that focuses on the early detection of cancer through non-invasive blood tests. Founded in 2018, the company utilizes advanced technologies such as artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in patients' blood. By leveraging machine learning, Delfi develops innovative testing systems aimed at recognizing cancer-associated cell-free DNA fragments, thereby enabling healthcare professionals to detect cancer at its most treatable stage. This approach facilitates timely and effective treatment options, ultimately aiming to improve patient outcomes and recovery speed.

Noctrix Health, Inc. is an early-stage medical device company based in Menlo Park, California, founded in 2018. The company specializes in the development of therapeutic wearable devices aimed at treating chronic neurological and sleep disorders. By focusing on innovative therapies, Noctrix Health seeks to address the unmet needs of patients suffering from these conditions.

Scorpion Therapeutics, Inc. is a biotechnology company focused on developing next-generation precision oncology technologies aimed at improving cancer treatment. Founded in 2020 and based in Boston, Massachusetts, the company specializes in creating precision oncology drugs that target known oncogenes, address currently undruggable cancer targets, and explore new therapeutic targets. By integrating advanced technologies in target discovery, medicinal chemistry, and translational medicine, Scorpion Therapeutics seeks to expand the reach of precision medicine to a broader patient population. The company's approach is designed to unlock novel small-molecule drugs that can overcome the limitations of existing therapies, thereby enhancing treatment options for cancer patients.

Ikena Oncology is dedicated to bringing next generation oncology therapies to patients suffering from cancer. Ikena Oncology are committed to leveraging our unique understanding of the complex biologic pathways that drive the formation and spread of cancers to discover and develop novel, patient-directed therapies. Selecting patients for treatment in clinical studies with biomarkers we develop is at the core of our strategy.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral, small-molecule drugs for the treatment of cancer and liver diseases, particularly non-alcoholic steatohepatitis (NASH). Founded in 2017 and headquartered in Foster City, California, with additional offices in Shanghai, the company leverages its expertise in disease biology and medicinal chemistry to advance a pipeline of innovative therapeutic candidates. Key products include TERN-101, a non-bile acid farnesoid X receptor agonist, and TERN-201, an inhibitor of semicarbazide-sensitive amine oxidase. Terns Pharmaceuticals aims to address significant unmet medical needs both in China and globally through its efficient drug discovery model and extensive clinical development capabilities.

Cullinan Pearl, a subsidiary of Cullinan Oncology, focuses on developing innovative cancer therapies, specifically targeting Epidermal Growth Factor Receptor (EGFR) exon 20 mutations through its orally available tyrosine kinase inhibitor. The company is part of a broader strategy to create a diverse portfolio of oncology therapeutics, relying on a combination of internal research and collaborative efforts with academic institutions and pharmaceutical companies. This approach allows Cullinan Pearl to efficiently advance its drug development programs, with a commitment to rapidly discontinue any projects that show limited potential based on early research findings. As part of its ongoing initiatives, Cullinan Pearl collaborates with Cullinan Oncology to support the development and commercialization of its therapies.

Edgewise Therapeutics is a clinical-stage biopharmaceutical company based in Boulder, Colorado, specializing in the development of small molecule therapies for severe musculoskeletal diseases. Founded in 2017, the company leverages its expertise in skeletal muscle physiology to create innovative treatments for genetically defined muscle disorders, including Duchenne, Becker, and limb girdle muscular dystrophies. Edgewise Therapeutics employs a precision medicine platform to identify and target key muscle proteins and modulators, aiming to address the underlying causes of these conditions. Additionally, the company has established a state-of-the-art research facility to enhance its capabilities in understanding muscle adaptation and injury related to disease.

RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. The company specializes in developing tumor-targeted small molecule medicines that utilize radioisotopes, particularly focusing on alpha-emitting isotopes like Actinium-225 for the treatment of solid tumors. RayzeBio aims to improve cancer treatment outcomes by creating a robust pipeline of radiopharmaceuticals targeting validated oncology drug targets. Its portfolio includes multiple drug candidates at various stages of development, ranging from discovery to late-stage clinical programs, addressing significant market opportunities in the field of cancer therapeutics.

Enliven Therapeutics is a clinical-stage precision oncology company dedicated to the discovery and development of innovative small molecule therapies aimed at enhancing patient outcomes. The company focuses on addressing critical challenges in cancer treatment, such as tolerability, combinability, resistance, and disease progression, particularly in the context of brain metastases. Enliven's lead product candidates include ELVN-001, a selective small molecule kinase inhibitor targeting the BCR-ABL gene fusion associated with chronic myeloid leukemia, and ELVN-002, an irreversible HER2 inhibitor designed to penetrate the central nervous system and target both wild type HER2 and related variants. Through its advanced discovery process, Enliven Therapeutics aims to create first-in-class therapies that improve the quality of life for patients facing cancer.

Syros Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead candidates, SY-1425, a selective retinoic acid receptor alpha agonist currently undergoing Phase II trials for specific patients with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor in Phase I trials for select advanced solid tumors. Syros employs a proprietary platform that integrates assay technologies, bioinformatics, and biological insights to map gene regulatory circuits and modulate gene expression, positioning itself as a leader in gene control research. Additionally, Syros has established collaborations, including a target discovery agreement with Incyte Corporation focused on myeloproliferative neoplasms, and a licensing agreement with TMRC Co. Ltd. for tamibarotene's development and commercialization. Founded in 2011, Syros Pharmaceuticals aims to address significant unmet medical needs in oncology and beyond.

VIVUS, Inc. is a specialty pharmaceutical company based in Campbell, California, focused on the development and commercialization of therapeutic products for obesity, diabetes, sleep apnea, and sexual health. The company offers Qsymia, a treatment for obesity designed to assist adults with a body mass index of 30 or greater, or 27 or greater with weight-related health issues, in managing their weight alongside a reduced-calorie diet and increased physical activity. VIVUS also provides PANCREAZE, which addresses exocrine pancreatic insufficiency, and STENDRA/SPEDRA, an oral medication for erectile dysfunction. Additionally, the company is advancing its pipeline with ongoing clinical studies for Qsymia to treat conditions such as obstructive sleep apnea and diabetes, as well as VI-0106 for pulmonary arterial hypertension. VIVUS has established collaborative agreements with several pharmaceutical firms to enhance its research and development efforts. Founded in 1991, VIVUS continues to focus on innovative solutions that address significant health issues facing patients.

Invivyd is a biotechnology company focused on developing advanced antibodies to neutralize SARS-CoV-2, SARS-CoV-1, and other potentially emerging coronaviruses. Founded in 2020 and headquartered in Waltham, Massachusetts, the company aims to create best-in-class therapeutic and prophylactic treatments that surpass the efficacy of existing antibody programs. Its innovative portfolio features multiple non-competing antibodies, each targeting distinct viral epitopes, which is designed to minimize the risk of viral escape. By leveraging cutting-edge antibody discovery technologies, Invivyd seeks to enhance the potency and durability of its antibody candidates, addressing a critical need in the ongoing fight against coronaviruses.

Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing therapies aimed at protecting, repairing, and restoring hearing. The company focuses on a range of hearing disorders, including those related to cancer treatments, cystic fibrosis, noise exposure, age-related and genetic hearing loss, as well as tinnitus. It utilizes advanced techniques such as single-cell genomics, bioinformatics, and precision gene therapy technologies to enhance its understanding of inner ear pathology and to develop effective treatments. Decibel Therapeutics also offers expertise in drug delivery to the inner ear, imaging, and pharmacokinetic modeling, contributing to innovative therapeutic approaches for patients experiencing various forms of hearing loss. Founded in 2013 and based in Boston, Massachusetts, Decibel Therapeutics was previously known as Hearing, Inc. before rebranding in 2014.

Cytek Biosciences, Inc. specializes in manufacturing and selling innovative flow cytometry tools and equipment for cancer and cell biology research. The company offers advanced instruments such as the Cytek Aurora and Cytek Northern Lights, which are full-spectrum flow cytometers designed for high-resolution and high-sensitivity cell analysis. Additionally, Cytek provides the DxP Athena system, which utilizes its proprietary technology to resolve dim populations in multicolor formats, along with the QbSure quality control program to ensure optimal performance of cytometers. The company also develops proprietary cFluor reagents that enhance the performance of its instruments in complex multicolor environments. Headquartered in Fremont, California, Cytek has expanded its global presence with locations in Maryland, the Netherlands, Japan, and China, aiming to make flow cytometry more accessible for researchers and clinicians worldwide.

Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief. Q32 Bio consists of a team of scientists and industry veterans with strong expertise in immunology. The team has a strong track record of discovering and developing new and innovative therapies.

Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief. Q32 Bio consists of a team of scientists and industry veterans with strong expertise in immunology. The team has a strong track record of discovering and developing new and innovative therapies.

Caris Life Sciences is a biotechnology company based in Irving, Texas, specializing in precision medicine and cancer treatment. Founded in 1996, the company develops and commercializes advanced diagnostic technologies, including anatomic pathology and molecular profiling, to enhance the understanding of cancer biology. Its services encompass comprehensive molecular analyses of patient samples, integrating genomic, transcriptomic, and proteomic profiling through the Caris Molecular Intelligence platform. This platform aids physicians and cancer patients in making informed and personalized treatment decisions by revealing the molecular blueprint of complex diseases. Caris Life Sciences serves a global customer base through distributors in regions including the United States, Europe, and Australia, and maintains a strategic collaboration with Debiopharm International SA. The company is committed to improving patient outcomes through innovative scientific advancements and a focus on quality care.

Azura Ophthalmics is a clinical-stage company focused on developing innovative treatments for Meibomian Gland Dysfunction (MGD), a leading cause of dry eye disease (DED). By addressing the underlying causes of MGD, Azura aims to improve the health and quality of life for millions affected by this and other ocular surface diseases, where effective treatment options are often limited. The company is advancing a unique portfolio of compounds in conjunction with a novel drug delivery platform, enabling healthcare professionals to better manage these conditions. Based in Tel Aviv-Yafo, Israel, Azura also has operational presence in Australia and the United States, supported by a management team with a strong track record in the development and commercialization of novel ocular therapies.

Nuvation Bio Inc., a biopharmaceutical company, focuses on the development of therapies for oncology. Its portfolio includes various oncology programs with multiple drug development candidates. Nuvation Bio Inc.was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. The company was founded in 2018 and is based in New York, New York with an additional office in San Francisco, California.

Olema Oncology is a clinical-stage biopharmaceutical company dedicated to developing targeted therapies for women's cancers, particularly estrogen receptor (ER)-positive breast cancer. The company's lead candidate, OP-1250, is an ER antagonist and selective ER degrader currently undergoing Phase 1/2 clinical trials for the treatment of metastatic or locally advanced, ER-positive, and human epidermal growth factor receptor 2-negative breast cancer. Olema's research focuses on utilizing its expertise in endocrine-driven cancers and the molecular mechanisms of the ER to create more effective treatments that aim to improve patient outcomes. In addition to OP-1250, Olema is advancing another drug candidate, OP-3136, further enriching its pipeline. Established in 2006 and headquartered in San Francisco, California, Olema is committed to transforming the standard of care for women facing these challenging diagnoses.

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing tissue-targeted therapeutics for cancer, chronic viral infections, and other serious diseases. The company's lead product candidate, SBT6050, is currently in a Phase I/Ib clinical trial. It is a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody, specifically targeting tumors such as breast, gastric, and non-small cell lung cancers. Additionally, Silverback is advancing SBT6290, a preclinical candidate that targets Nectin4, expressed in various cancers, and SBT8230, aimed at treating chronic hepatitis B virus infection. Utilizing its proprietary ImmunoTAC technology, Silverback aims to develop a new generation of therapies that can be systemically delivered yet act locally at disease sites, thereby modulating critical disease pathways that were previously considered inaccessible.

Novellus is a biotechnology company working to develop engineered cellular medicines. The company uses its non-immunogenic mRNA molecules to reprogram and gene-edit cells safely, and with high efficiency. They engineer precision medicines for patient segments and select from its technology toolbox for in vivo, ex vivo, allogeneic and autologous delivery. Novellus platform enables the high-level expression of gene-editing and cell-reprogramming proteins for high-specificity gene repair and both autologous and allogeneic cell therapies. The company is advancing its lead program, a breakthrough therapy for a rare dermatologic disease, through pre-clinical studies. Novellus was founded in 2015 and is headquartered in Cambridge, Massachusetts, United States.

CoreMap, Inc. develops a diagnostic technology for electrophysiologists for treating atrial fibrillation. It offers CoreMap micro-electrode solution for mapping tissue properties (ability to map sequentially). The company also provides CoreMap ultra-high resolution electrodes reveal the details of activation despite fibrillation. The company was incorporated in 2016 and is based in Winooski, Vermont.

E-Scape Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapies for neurodegenerative diseases. Established in 2015 and headquartered in South San Francisco, California, the company aims to improve the lives of patients suffering from conditions such as Alzheimer’s disease, Parkinson’s disease, and sphingolipid storage disorders. E-Scape Bio is advancing a pipeline of therapeutics that target specific genetic drivers of these diseases, including ESB1609, a small molecule S1P5 receptor agonist for CNS lysosomal storage disorders, and ESB5070, a kinase inhibitor designed for Parkinson’s disease patients with the LRRK2 G2019S variant. Additionally, the company is developing a program targeting ApoE4 in Alzheimer’s disease, emphasizing its commitment to precision medicine in treating genetically defined subpopulations.

NeuroPace, Inc. specializes in the design, development, manufacturing, and marketing of implantable devices aimed at treating neurological disorders through responsive stimulation. The company's flagship product, the RNS System, is specifically designed for patients with medically refractory partial epilepsy. This system includes a small implantable neurostimulator that monitors brain activity and delivers electrical pulses to targeted areas to prevent seizures. The RNS System comprises various components, such as depth leads and cortical strip leads for implantation, along with external devices like a programmer that allows healthcare professionals to communicate with the neurostimulator. Founded in 1997, NeuroPace is headquartered in Mountain View, California.

Erasca, Inc. is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for cancers driven by the RAS/MAPK pathway. Founded in 2018 and headquartered in San Diego, California, Erasca utilizes its oncology pattern recognition algorithm (OPRA), an artificial intelligence-driven drug discovery platform, to analyze large-scale data sets and uncover novel tumor biology that can inhibit key cancer pathways. The company is advancing multiple drug candidates, including Naporafenib, an innovative pan-RAF inhibitor aimed at treating NRAS mutant melanoma and other RAS/MAPK-driven tumors, as well as ERAS-007 and ERAS-601, which are oral inhibitors targeting ERK1/2 and SHP2, respectively. Through collaborations with academic and biopharmaceutical partners, Erasca aims to expand its pipeline and provide new therapeutic options for cancer patients.

Kinnate Biopharma develops precision oncology therapeutics to treat patients with genomically-defined cancers. Its mission is to expand the reach of targeted therapeutics by developing products for underserved populations. The company utilizes its deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine. Its programs include candidates in preclinical development for cancers that are driven by specific oncogenic alterations in either the BRAF kinase gene or in the FGFR2 and FGFR3 kinase genes.

Prelude Therapeutics is a clinical-stage biopharmaceutical company based in Wilmington, Delaware, founded in 2016. The company focuses on discovering and developing small molecule therapies designed to target critical mechanisms driving cancer growth and resistance. Its pipeline includes several candidates currently in Phase 1 clinical trials, such as PRT543, aimed at treating solid tumors and myeloid malignancies, and PRT811, which targets solid tumors like glioblastoma multiforme. Other development programs include PRT1419, a selective inhibitor of an anti-apoptotic protein, PRT2527, an inhibitor of CDK9, PRT-SCA2 for genomically selected cancers, and PRT-K4 for solid tumors. Prelude Therapeutics aims to provide innovative treatment options for patients facing refractory cancers.

ImmPACT Bio USA Inc. is a cell therapy company aiming to develop potent and selective engineered T-cells for the treatment of solid tumors. The Company's technology enables targeting loss-of-gene features of solid tumor cells, sparing normal, healthy tissues.

Aerin Medical Inc. is a health technology company based in Sunnyvale, California, focused on developing non-invasive treatment solutions for nasal breathing disorders. Founded in 2011, the company specializes in therapeutic devices that utilize low-power radiofrequency energy to remodel nasal soft tissues, effectively addressing the underlying causes of conditions such as nasal obstruction and chronic rhinitis. Aerin Medical offers procedures and devices, including the VivAer procedure and the RhinAer procedure, along with their corresponding styluses, which allow ENT physicians to treat nasal airway conditions in an office setting under local anesthesia. These innovative solutions aim to improve patient outcomes by providing safe, quick, and effective relief from chronic nasal symptoms while minimizing downtime.

MobileODT Ltd specializes in developing optical diagnostic devices and software focused on early cancer detection, particularly cervical cancer. The company's flagship product, the EVA COLPO, is a portable, internet-connected colposcope that is FDA-cleared and designed for ease of use. MobileODT also offers EVA SANE, a secure platform for managing patient information, and EVA WELL, a digital visualization tool for gynecologic exams. Their offerings include a mobile application for remote image capture and patient tracking, along with a cloud-based portal for collaboration and reporting. In addition, the company provides tools for documenting violence and abuse and plans to expand its product line to cover other medical areas such as ENT and dermatology. Established in 2012 and headquartered in Tel Aviv, Israel, with an office in New York, MobileODT has gained recognition in various markets, particularly the United States, where it is becoming a standard for visual diagnostics in healthcare settings.

GentiBio, Inc. is a biotherapeutics company focused on developing engineered regulatory T cells (EngTregs) to treat a range of conditions, including autoimmune, alloimmune, autoinflammatory, and allergic diseases. Founded in 2020 and based in Boston, Massachusetts, with additional locations in Seattle and Israel, GentiBio utilizes a proprietary platform that combines autologous and allogeneic EngTregs. This innovative approach aims to restore immune tolerance and address the limitations found in current regulatory T-cell therapies. The company was co-founded by experts in Treg biology and synthetic immunology, emphasizing its commitment to addressing the underlying causes of diseases linked to immune system dysfunction.